# US 2010/0168073 A1 · Method for treating and/or preventing retinal diseases with sustained release corticosteroids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168073 A1
- Document ID: US20100168073A1
- Status: Published application
- Kind: A1
- Application number: 12/684,341
- Filed: 2010-01-08
- Published: 2010-07-01
- Earliest claimed: 1999-03-22
- Assignees: pSivida US, Inc.
- Inventors: Paul Ashton
- Web page: https://patentgrep.com/patent/US20100168073A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0051: {Ocular inserts or implants}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A sustained release device including fluocinolone acetonide (FA) disposed therein, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate over a time course of at least 4 weeks after implantation, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

### Claim 18

A sustained release device including FA disposed therein, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that results in damage to a patient's ocular tissue.

### Claim 19

A sustained release device including (FA) disposed therein, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, or diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

### Claim 20 (depends on 17, 18)

The device of claim 17, 18, or 19, wherein the aqueous humor FA concentration is less than about 0.05 μg/ml.

### Claim 21 (depends on 17, 18)

The device of claim 17, 18, or 19, wherein the FA is released with pseudo zero order kinetics.

### Claim 22 (depends on 17, 18)

The device of claim 17, 18, or 19, configured to have a release rate for said FA over said time course.

### Claim 23 (depends on 17, 18)

The device of claim 17, 18, or 19, wherein said time course is at least 100 days.

### Claim 24 (depends on 17, 19)

The device of claim 17 or 19, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that results in damage to a patient's ocular tissue.

### Claim 25 (depends on 24)

The device of claim 24, wherein the release rate for said FA over said time course is effective for reducing one or more of senile macular degeneration, chronic posterior or and pan uveitis, or diabetic macular edema.

### Claim 26 (depends on 17, 18)

The device of claim 17, 18, or 19, which release rate does not produce ocular steroid-induced toxicity.

### Claim 27 (depends on 18, 19)

The device of claim 18 or 19, which device is effective for reducing senile macular degeneration, chronic posterior or pan uveitis, or diabetic macular edema.

### Claim 28

A sustained release device including a steroid disposed therein, which device is dimensioned for implantation in the vitreal cavity of a patient's eye and configured to release a therapeutically effective amount of steroid, which amount does not produce ocular or systemic steroid-induced toxicity.

### Claim 29

A sustained release device including a steroid disposed therein, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to release a therapeutically effective amount of steroid, which amount does not produce ocular or systemic steroid-induced toxicity.

### Claim 30 (depends on 28, 29)

The device of claim 28 or 29, wherein the steroid is released with pseudo zero order kinetics.

### Claim 31

A sustained release device including FA disposed therein, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate over a time course of at least 4 weeks after implantation, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

### Claim 32

A sustained release device including FA disposed therein, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that results in damage to a patient's ocular tissue.

### Claim 33

A sustained release device including FA disposed therein, which device is dimensioned for implantation in the posterior segment of a patient's eye and configured to have a release rate for said FA to produce a sustained and therapeutic concentration of said FA over a time course of at least 4 weeks effective for reducing neovascularization, edema, diabetic retinopathy, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization, chronic posterior and pan uveitis, neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, or neovascularization due to penetration of the eye or ocular injury, which release rate results in an aqueous humor FA concentration less than one tenth the vitreous FA concentration.

### Claim 34 (depends on 31, 32)

The device of claim 31, 32, or 33, wherein the aqueous humor FA concentration is less than about 0.05 μg/ml.

### Claim 35 (depends on 31, 32)

The device of claim 31, 32, or 33, wherein the FA is released with pseudo zero order kinetics.

### Claim 36 (depends on 31, 32)

The device of claim 31, 32, or 33, configured to have a release rate for said FA over said time course.

### Claim 37 (depends on 31, 32)

The device of claim 31, 32, or 33, wherein said time course is at least 100 days.

### Claim 38 (depends on 31, 33)

The device of claim 31 or 33, which release rate results in an aqueous humor FA concentration which does not cause an increase in intraocular pressure over said time course that results in damage to a patient's ocular tissue.

### Claim 39 (depends on 38)

The device of claim 38, wherein the release rate for said FA over said time course is effective for reducing one or more of senile macular degeneration, chronic posterior or and pan uveitis, or diabetic macular edema.

### Claim 40 (depends on 31, 32)

The device of claim 31, 32, or 33, which release rate does not produce ocular steroid-induced toxicity.

### Claim 41 (depends on 32, 33)

The device of claim 32 or 33, which device is effective for reducing senile macular degeneration, chronic posterior or pan uveitis, or diabetic macular edema.
